A team at the University of Minnesota says it has built the first synthetic cell that completes an entire life cycle on its own: it selects, replicates its genome, grows, acquires resources, and divides — without being built from, or hosted inside, any living cell. The researchers, associate professors Kate Adamala and Aaron Engelhart, call the system SpudCell. The work is described in a paper titled “A Chemically Defined Synthetic Cell Capable of Growth and Replication,” released July 1, 2026 alongside the launch of a new public-benefit research organization, Biotic, built to support this kind of work going forward.
“We’ve replicated in chemistry what only used to be possible in biology: the complete set of behaviors of a cell,” Adamala said.
What makes SpudCell different from earlier synthetic-biology milestones
Synthetic biology has produced landmark synthetic genomes before. But those projects — most famously the J. Craig Venter Institute’s minimal-genome work — started from a synthetic genome and transplanted it into the emptied cytoplasm of an existing living cell, which still supplied the membrane, ribosomes, and replication machinery. That living “chassis” did the biological heavy lifting.
SpudCell, according to the researchers, skips that step entirely. It is assembled from nonliving chemical components — no borrowed membrane, no scavenged cellular machinery from an existing organism. That is the headline claim worth sitting with: a system built from scratch out of chemistry that nonetheless grows, divides, and reproduces itself the way a living cell does.
Inside SpudCell: a 90-kilobase genome and division without a cytoskeleton
SpudCell’s genome is 90 kilobase pairs, split across seven separate DNA plasmids so different functions can be programmed and swapped modularly. Notably, that is smaller than the roughly 113 kbp previously theorized to be the practical minimum for a genome capable of supporting a full cell life cycle — suggesting synthetic systems can be engineered leaner than researchers had assumed necessary.
Real cells typically rely on a cytoskeleton to physically pull a dividing cell apart. SpudCell doesn’t have one. Instead, the researchers report, membrane-surface proteins generate mechanical stress that splits the membrane on its own — a genetically encoded division mechanism built without borrowing biology’s usual toolkit for the job.
Darwinian selection, demonstrated from scratch
Completing a life cycle is one claim. Evolving is another, and the researchers report evidence of that too: across five generations, a genetic variant of SpudCell that produced more fusion proteins outcompeted the original version — a small but real demonstration of Darwinian selection acting on a wholly synthetic organism, not a modified natural one.
Taken together — genome replication, growth, resource acquisition, genetically encoded division, and heritable variation under selection — that is the specific combination the researchers point to when they describe SpudCell as life-cycle-complete, rather than simply a synthetic genome or a synthetic membrane in isolation.
Biotic: an infrastructure nonprofit instead of an exclusive license
The more unusual move here may be organizational rather than biochemical. Rather than route SpudCell’s underlying methods through a conventional university technology licensing office and an exclusive commercial license, Adamala and Engelhart launched Biotic as a public-benefit research and engineering institution alongside the paper itself. Biotic’s stated aim is to build shared technical infrastructure for synthetic-cell engineering and keep it open to researchers internationally, rather than have the tooling and protocols sit behind one lab’s or one company’s walls.
That is a genuine, if quiet, tech-transfer story: a foundational synthetic-biology platform being deliberately routed toward an open, shared-infrastructure model at the moment of publication, rather than the more conventional path of patent filing followed by exclusive licensing. Research institutions and funders that track how foundational biotechnology gets commercialized — or, in this case, deliberately isn’t — will likely be watching how Biotic’s governance and access model actually functions in practice.
An open question worth asking: does synthetic life need its own biosafety category?
The phys.org report on SpudCell doesn’t itself address biosafety classification or oversight, and nothing here should be read as a claim that regulators have flagged this specific work. But the achievement invites a real question that institutional biosafety and biosecurity frameworks weren’t built to answer cleanly.
Existing containment and risk-classification systems — frameworks like the U.S. Biosafety in Microbiological and Biomedical Laboratories (BMBL) guidance and the biosafety-level system built on it — were designed around a fairly consistent assumption: the organism in question is a known biological entity, modified to some degree, and its risk profile can be reasoned about relative to a natural pathogen or host it resembles. A cell with no natural counterpart at all, assembled from nonliving chemistry, that nonetheless grows, divides, and undergoes selection on its own, doesn’t map neatly onto that logic. Is it lower risk because it shares no lineage with anything pathogenic, or does the very fact that it’s an autonomously reproducing, evolving system built outside biology’s existing safety rails argue for more scrutiny, not less?
That is not a rhetorical question with an obvious answer, and this article isn’t claiming one. It’s the kind of classification gap that institutional biosafety committees, funders, and dual-use-research-of-concern policy bodies are likely to need to work through explicitly as wholly synthetic, life-cycle-complete organisms move from a single demonstration to a broader research tool — particularly given Biotic’s stated intent to make the underlying methods more widely accessible.
Why this matters beyond one lab
For research administrators and institutional oversight bodies, SpudCell is a useful marker of how fast the ground can shift under existing review processes. A synthetic-biology protocol that clears an institutional biosafety committee today was very likely written with modified-organism risk in mind, not from-scratch synthetic life. As platforms like this move from a single paper to shared, openly distributed infrastructure — which is explicitly Biotic’s goal — the institutions receiving that infrastructure will need review processes that can actually classify what they’re looking at.
Primary source: “World’s first fully synthetic cell completes an entire life cycle, and it could revolutionize science”, Phys.org, July 2026, reporting on the paper “A Chemically Defined Synthetic Cell Capable of Growth and Replication” and the launch of Biotic.
